Core Viewpoint - The company has decided to terminate its stock issuance plan to specific investors, which has been in progress for over two years, due to changes in market conditions and regulatory scrutiny [2][3][4]. Group 1: Termination of Stock Issuance - The stock issuance plan aimed to raise up to 500 million yuan for working capital but faced criticism due to a significant price difference between the issuance price of 8.96 yuan per share and the market price of 15.52 yuan per share, representing a 73.21% premium [3][5]. - The company emphasized that the termination of the stock issuance will not have a significant adverse impact on its normal business operations and will not harm the interests of shareholders, especially minority shareholders [3][4]. Group 2: Financial Performance and Concerns - The company has faced scrutiny regarding its high sales expenses, which were 185 million yuan, 156 million yuan, and 167 million yuan from 2021 to 2023, accounting for 37.88%, 41.45%, and 41.20% of revenue, respectively, indicating a higher rate than industry peers [5][8]. - The company's main pharmaceutical product, Bimodine Ointment, saw a revenue decline of 25.15% in 2024, with total revenue from pharmaceuticals dropping from 12.23% in 2023 to 9.80% in 2024 [8][9]. Group 3: Regulatory and Compliance Issues - The company has previously received warnings from regulatory bodies for disclosure violations, including delays in reporting significant litigation and changes in core business operations, which have raised concerns about its compliance and risk management practices [7][10]. - The termination of the stock issuance plan may lead to increased regulatory scrutiny, especially regarding the fairness of pricing in related party transactions [4][6].

6月5日，冠昊生物今日收盘16.54元，下跌1.25%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到157.24倍，总市值43.86亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入9479.71万元，同比3.67%；净利润1486.61万 元，同比3.30%，销售毛利率77.05%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)112冠昊生物157.24159.967.8743.86亿行业平均 50.9748.964.68108.42亿行业中值36.6736.602.4749.87亿1天益医疗-1782.30-3052.891.9022.71亿2澳华内 镜-692.58347.365.5572.99亿3诺唯赞-414.64-490.412.2788.73亿4爱朋医疗-382.20290.364.6031.36亿5博晖 创新-331.28525.693.5448.61亿6奥精医疗-149.94-219.761.9827.83亿7硕世生物-138.80-2028.201.2440.60亿 8睿昂基因-101.98-83.721.4513.20亿9康泰医学-86.93-73.4 ...

最新一期业绩显示，2025年一季报，公司实现营业收入9479.71万元，同比3.67%；净利润1486.61万 元，同比3.30%，销售毛利率77.05%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)110冠昊生物131.67133.956.5936.72亿行业平均 49.1147.374.60105.87亿行业中值35.8936.632.3948.39亿1天益医疗-1748.54-2995.051.8722.28亿2澳华内 镜-629.96315.965.0566.39亿3诺唯赞-396.80-469.312.1884.92亿4爱朋医疗-348.40264.684.2028.59亿5博晖 创新-323.49513.323.4547.46亿6硕世生物-133.76-1954.591.2039.13亿7奥精医疗-130.30-190.981.7224.18亿 8睿昂基因-100.25-82.311.4212.98亿9康泰医学-86.69-73.243.0957.06亿10中红医疗-72.51-57.830.9250.39亿 11华大智造-56.78-50.383.91302.72亿 来源：金融界 5 ...

序号股票简称PE(TTM)PE(静)市净率总市值(元)110冠昊生物127.86130.086.4035.66亿行业平均 49.5147.734.57106.36亿行业中值36.1737.202.5148.58亿1天益医疗-1784.15-3056.061.9022.74亿2澳华内 镜-619.74310.834.9665.31亿3诺唯赞-415.76-491.732.2888.97亿4爱朋医疗-370.37281.374.4630.39亿5博晖 创新-330.72524.813.5348.52亿6硕世生物-137.27-2005.841.2340.15亿7奥精医疗-130.15-190.761.7224.15亿 8睿昂基因-105.86-86.911.5013.70亿9康泰医学-86.99-73.503.1057.26亿10中红医疗-73.12-58.330.9350.82亿 11华大智造-58.05-51.514.00309.51亿 冠昊生物科技股份有限公司的主营业务是致力于开发具有自主知识产权的新产品、新技术,将提升产品 质量、优化产品结构视为企业发展的核心驱动力,积极应对市场挑战,不断调整优化营销策略 ...